Ivermectin is a novel medication that continues to be investigated in several areas beyond its established anti-parasitic uses. The research landscape is actually quite interesting, particularly in cancer, malaria transmission, infectious diseases and dermatology, yet those of us who are using it successfully to treat our various health issues, demand more: more research, more sources, more approvals.
Since the early 1900s, billions of dollars have been invested toward cancer research, with the first scientific link dating back to the early 1770s, when chimney soot was linked to cancer. To date, the US Federal government alone has invested between $200-$300 billion dollars on the National Cancer Act — unfortunately, there has not been any positive resolve.
So, out of curiosity, we turned to AI software and asked the following question to see what the response was: “If Ivermectin shows promising results for people with a cancer diagnosis, why is not being researched globally, far and wide, immediately?”
Prepare for the answer, friends, as this is what AI responded with:
– –
1. The evidence has to cross a very high clinical threshold (interpretation: “it’s too much work”)
2. Cancer isn’t one disease (interpretation: “it would be too challenging”)
3. Ivermectin has an unusual commercial problem (interpretation: “it’s not worth our investment”)
4. There is a funding problem (as above)
– –
Bottom line: the health and future of over half of the world’s population lies in these two facts: “It’s too much work, for which we can’t be reimbursed.”
The commerciability of Ivermectin
Ivermectin is an old, simple, inexpensive generic drug. There isn’t a company sitting on a new patent that could potentially justify spending hundreds of millions of dollars developing it into a new cancer drug.
In the eyes of Big Pharma, that’s very different from developing a brand-new molecule.
A pharmaceutical company can spend enormous amounts on laboratory research, toxicology, formulation testing, pharmacokinetic studies, Phases 1, 2 and 3 trials, and regulatory submissions, only to not recoup that investment. With an inexpensive generic drug, the financial incentive is substantially weaker.
The funding problem
We believe – as do thousands of our clients – that there is enough mechanistic and preclinical evidence to make a claim for research scientifically legitimate: why not? why not now? if there are hundreds of thousands of people being diagnosed with cancer, and these are seeing remarkable results by using Ivermectin as part of their protocol, should that not be enough to justify global research?
What about widening the window of “Right To Try”? At least enough to allow for individuals who have otherwise been sent to Hospice to await their death, a possibility of curing their cancer? Or at least for a chance at extending the quality of their lives by a few more months/years with their loved ones..?
What about for our children, who deserve to live, rather than spend their days being poked and prodded at hospitals?
A recent scoping review identified 1,427 records and 43 preclinical studies examining ivermectin across cancers including breast, colorectal, glioblastoma and haematological malignancies. The proposed mechanisms include effects on P-glycoprotein, mitochondrial function and several cancer-associated signalling pathways. The authors specifically conclude that “robust clinical trials are needed”.
And albeit small trials are yet better than none, researchers are now beginning human trials:
The University of Florida’s ICONIC Phase 2 trial, for example, is currently listed on ClinicalTrials.gov as not yet recruiting, with an estimated start in September 2026 and approximately 80 participants. It is specifically designed to determine whether ivermectin produces measurable immune modulation when combined with checkpoint inhibition (which we already know the answer to).
Overall in Florida, four institutions have already received millions in research grand funding for ivermectin in cancer use; including Florida International University ($1.4m), Florida State University ($365k), Tampa General Hospital ($711k) and University of Miami ($1.47m).
Cedars-Sinai Medical Center in Los Angeles is also investigating ivermectin in metastatic triple-negative breast cancer.
The University of Yamanashi’s Omura Satoshi Memorial Institute has already an active ivermectin-based programme for difficult-to-treat childhood cancers and other refractory cancers.
The National Cancer Institute has already initiated internal preclinical laboratory studies to test ivermectin’s properties in cancer.
Does the U.S. “Right to Try” law allow access to ivermectin?
The United States does have a federal Right to Try law, which allows certain patients with serious or life-threatening conditions to seek access to eligible investigational drugs that have completed Phase 1 clinical trials but have not yet received FDA approval. However, existing ivermectin does not qualify under this law because ivermectin is already FDA-approved for certain parasitic infections. This means a patient cannot claim a federal Right to Try to obtain ivermectin simply because they wish to use it for an unapproved condition, such as cancer.
There is, however, an important distinction: because ivermectin is an FDA-approved human medication, a physician may prescribe it for an off-label use when they independently determine that doing so is medically appropriate for an individual patient. Off-label prescribing is different from Right to Try and does not require the drug to qualify as an investigational medicine. A physician is not obligated to prescribe ivermectin, however, and must consider the available evidence, potential risks, drug interactions and their professional responsibilities when making that decision. Unfortunately, they may feel that in doing so, they risk their reputation and possibly, their licence.
What about in Canada?
Canada does not have a U.S.-style federal “Right to Try” law that gives patients an independent legal right to obtain an investigational drug (yet). However, there is an important distinction when it comes to ivermectin. Ivermectin is an approved prescription medication in Canada for certain conditions, and Health Canada’s Special Access Program is intended for drugs that are not marketed or authorized for sale in Canada. Importantly, Health Canada’s own Special Access Program guidance states that practitioners who wish to use a drug that is already approved for sale in Canada for an indication different from its approved indication do not need to file a Special Access Program request. This is the basis for off-label prescribing in Canada.
This means that a Canadian physician may, where they consider it medically appropriate, prescribe an approved drug such as ivermectin for an off-label indication, including an indication that is still being investigated in clinical research. This does not mean that a patient has an automatic “right” to receive ivermectin, nor does it require a physician to prescribe it. The decision rests with the treating practitioner, who must consider the available scientific evidence, potential benefits and risks, drug interactions and their professional obligations. If the medication itself were not authorized or marketed in Canada, a physician could potentially seek access through Health Canada’s Special Access Program, but the patient cannot apply directly and each request is assessed individually.
The research is there, so are the trials. Unfortunately, many people feel they need to hide from their doctors and keep their use of ivermectin and other repurposed drugs secret, so as to not lose the opportunity for doctor care – which is a shame because for them, it’s about a possibility for life, and they have a right to it.
What are the risks of taking ivermectin — without telling your health care team if you are on it?
Naturally, there are risks to taking any medication. We’ve already seen how much harm the Covid vaccination can do, yet we’re still being told they are “safe and effective”. There are countless side effects to taking Aspirin and Tylenol, yet they are still sold at every pharmacy and even at gas stations and convenience stores. Even the most natural foods, herbs and supplements also come with risks. When it comes to cancer and the possibility of a death sentence that conventional medications can provide, however, we believe the person with a diagnosis has the right to try because the alternative – without trying – is unacceptable.
We have seen that on various platforms, using ivermectin for cancer is touted as “interacting with chemo and radiation” and “toxic at higher doses”, however, if experimental trials haven’t been performed (as they claim), then what are they basing this advice on?
On one particular website, the advice is: “if you are taking or considering ivermectin, tell your oncologist. They are not here to judge you…” – unfortunately, we know patients are judged and even scalded for taking ivermectin. Thankfully, your doctor will not know.
To date at Harmova Health, we have been supporting thousands of clients with a deadly diagnosis, with what they consider to be “life-saving medications”. As one client shared with us:
“I was diagnosed with Gioblastoma and my doctor sent me home to die. He said there was nothing else they could do for me. After six months of taking the iver/meben combination, my doctor was shocked at how well I was doing! He said, ‘I don’t know what you are doing, and don’t tell me, but keep doing it because it’s working!’ I couldn’t be more thankful; I feel great and my doctor agrees it’s working!”
While we wait for change that is inevitable, we continue to offer these life-saving medications to our clients who have seen incredible positive results from taking them – because we do firmly believe the “Right to Try” is yours, as is your autonomy in health.
